CHICAGO, Apr 18: Giving an AIDS-fighting drug to men who are at high risk of HIV infection would cost billions, but it might be worth it terms of reducing infection rates, US researchers said on Monday. Since 2010, when a landmark study in the New England Journal of Medicine found that giving a daily dose of Gilead Sciences’ Truvada to men who have sex with men can reduce HIV infection rates by 44 percent, researchers have been trying to work out how to make this treatment approach financially feasible.
(agencies)
Trending Now
E-Paper
Follow our WhatsApp channel